Trials / Completed
CompletedNCT01630135
Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
Study FFR116364, a Double-blind, Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 261 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Years – 14 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety of GW685698X (55 µg/day, q.d.) nasal spray over a period of 2 weeks in Japanese paediatric subjects ages 6 to \< 15 years with perennial allergic rhinitis will be evaluated compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluticasone furoate | 55 mcg/day, intranasal, 2 weeks |
| DRUG | Placebo | Placebo, intranasal, 2 weeks |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2012-06-28
- Last updated
- 2017-01-11
- Results posted
- 2013-05-01
Locations
22 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01630135. Inclusion in this directory is not an endorsement.